Immunocore
IMCR
139 hedge funds and large institutions have $1.46B invested in Immunocore in 2024 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 59 increasing their positions, 34 reducing their positions, and 35 closing their positions.
170% more call options, than puts
Call options by funds: $9.85M | Put options by funds: $3.65M
74% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 34
5.61% more ownership
Funds ownership: 82.77% → 88.38% (+5.6%)
7% less funds holding
Funds holding: 149 → 139 (-10)
29% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 35
45% less capital invested
Capital invested by funds: $2.68B → $1.46B (-$1.22B)
86% less funds holding in top 10
Funds holding in top 10: 7 → 1 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$115M |
| 2 |
Primecap Management
Pasadena,
California
|
+$97M |
| 3 |
AC
Armistice Capital
New York
|
+$41.4M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$40.7M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$32.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$116M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$99.4M |
| 3 |
RI
RTW Investments
New York
|
-$58.6M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$58.5M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$45.9M |
IMCR Hedge Fund Activity: Q2 2024 in Review
139 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q2 2024, worth a combined $1.46B — down 45% from $2.68B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of IMCR and 25 opened new positions — a net loss of 10 holders — while 34 trimmed existing stakes and 59 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $115M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $116M sold.
- 139 institutional investors held Immunocore (IMCR) as of Q2 2024, down from 149 in Q1 2024.
- Funds reported $1.46B of Immunocore stock for Q2 2024, down 45% quarter-over-quarter.
- 25 funds opened new Immunocore positions in Q2 2024 and 35 closed out, a net change of -10 holders.
- The largest Immunocore buyer in Q2 2024 was T. Rowe Price Investment Management, an estimated $115M added.
- The largest Immunocore seller in Q2 2024 was Paradigm Biocapital Advisors, an estimated $116M sold.
Based on aggregated 13F filings for Q2 2024.